A matching-adjusted indirect treatment comparison (MAIC) of daratumumab–bortezomib–melphalan–prednisone (D-VMP) versus lenalidomide–dexamethasone continuous (Rd continuous), lenalidomide–dexamethasone 18 months (Rd 18), and melphalan–prednisone–thalidomide (MPT)

Abstract

D-VMP is a novel treatment for transplant-ineligible newly diagnosed multiple myeloma (TIE NDMM). D-VMP significantly prolonged PFS versus VMP in the ALCYONE trial. The FIRST trial investigated Rd given in 28-day cycles until disease progression, Rd for 18 cycles, and MPT for 12 cycles for TIE NDMM. As no randomized controlled trials comparing D-VMP to standard-of-care regimens such as those in FIRST are available, an MAIC was performed to assess relative OS and PFS for D-VMP from ALYCONE and Rd continuous, Rd 18, and MPT from FIRST. Individual patient data for D-VMP in ALCYONE were weighted to match aggregated baseline patient characteristics for each arm of FIRST. D-VMP significantly improved OS versus MPT and Rd 18, with a trend favoring D-VMP versus Rd continuous. D-VMP performed significantly better than all FIRST comparators for PFS. This MAIC demonstrates OS and PFS benefits for D-VMP versus Rd continuous, Rd 18, and MPT.

Keywords:

• Myeloma
• chemotherapeutic approaches
• matching-adjusted indirect comparison

Author contributions

MAD, TF, and SBG contributed to conception of study design, data acquisition, and analysis/interpretation; MC contributed to data analysis/interpretation; M-VM, BH, MP, AL, and MS contributed to conception of study design and data analysis/interpretation; SvB contributed to data acquisition and analysis/interpretation; SN contributed to conception of study design. All authors drafted and reviewed the manuscript, approved the final version, decided to publish this report, and vouch for data accuracy and completeness.

Disclosure statement

Meletios A. Dimopoulos received honoraria from, consulted for, and served on advisory committees for Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Novartis and received honoraria from and consulted for Takeda. Michele Cavo received honoraria from AbbVie, Adaptive Biotechnologies, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, and Takeda and served on advisory committees for Amgen, Bristol-Myers Squibb, Celgene, Janssen, and Takeda. Maria-Victoria Mateos served on advisory committees for AbbVie, Amgen, Celgene, GlaxoSmithKline, Janssen, Oncopeptides AB, and Takeda and received honoraria from Amgen, Celgene, Janssen, and Takeda. Thierry Facon served on speakers’ bureaus and advisory committees for Celgene, Janssen, and Takeda and served on advisory committees for Amgen, Karyopharm, Oncopeptides, and Sanofi. Bart Heeg is an employee of Ingress Health and received research funding from and consulted for Janssen. Sophie van Beekhuizen and Samron B. Gebregergish are employees of Ingress Health. Sandhya Nair, Marta Pisini, Annette Lam, and Mary Slavcev are employees of Janssen.

Data availability statement

The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.

Additional information

Funding

The analysis was funded by Janssen Global Services, LLC. Editorial and medical writing support were provided by Tara Abraham, PhD, of MedErgy and were funded by Janssen Global Services, LLC.